Intractable diseases are combination locks
From resistant cancers and infectious pathogens to neurodegeneration and metabolic dysfunction, a single key cannot cure the condition. Block one target, and the biological network adapts through a parallel pathway. CombixBio evaluates 400M drug combinations in silico to isolate the top 1,000 synergistic pairs. By compressing an impossible search space to a testable scale, we bring these top hits to the bench, experimentally verifying their mechanisms and therapeutic efficacy.
AI-accelerated Discovery Pipeline
We fuse high-throughput laboratory data from functional genomics with advanced generative AI reasoning. Our platform systematically analyzes how adaptive resistance routes are formed around single blocked cellular nodes. By modeling these dynamic disease networks, we rationally design multi-target combinations that close multiple critical pathways simultaneously, achieving profound synergy and durable responses where monotherapies fail.
Intelligent Panel Design
Compute optimal gene-pair screening panels by mapping large-scale genetic knockout data onto 3D Protein-Protein Interaction networks.
Combinatorial CRISPRi Screening
Suppress specific pairs of target loci simultaneously using dCas9-KRAB, generating clean, ground-truth phenotypic dropout data.
Digital Cellular Twins
Ingest high-dimensional functional genomics readouts into custom Transformer models to build predictive in silicomodels of adaptive signaling.
Virtual Synergy Profiling
Evaluate a 20,000 × 20,000 target/compound matrix in silico to isolate the top 1,000 most synergistic therapeutic regimens.
Why Combination Therapies
Monotherapy failure remains a critical clinical hurdle. Single agents often elicit early responses, but adaptive resistance limits their duration. At CombixBio, we overcome single-agent limitations by integrating AI-driven synergy profiling with mechanistic understanding of disease biology derived from functional genomics. Our platform reveals rational combinations that proactively bypass resistance mechanisms and reprogram signaling networks, paving the way for durable, transformative cures for intractable diseases.